Conditions are getting a bit more challenging for the drugmaker.

Eli Lilly (LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

AP Health Writer (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming ... Advertisement Article continues below this ad The company brought in $3.1 billion in sales from Mounjaro and ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Highlights,Eli Lilly reported third-quarter profits that fell short of Wall ... sed do eiusmod tempor incididunt ut labore et ...